MoonLake Immunotherapeutics (MLTX)
D
Pipeline Grade
Financial Position (from SEC Filings)
$298.5M
Cash & Equivalents
$66.3M
Quarterly Burn Rate
14 mo
Est. Cash Runway
$1,355M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (7)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06768671 | An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With ... | PHASE3 | Active Not Recruiting | 35 |
| NCT07223138 | A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Ps... | PHASE3 | Enrolling By Invitation | 1,560 |
| NCT07007637 | A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Mo... | PHASE3 | Enrolling By Invitation | 835 |
| NCT06411379 | Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With M... | PHASE3 | Active Not Recruiting | 418 |
| NCT06411899 | A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With... | PHASE3 | Active Not Recruiting | 422 |
| NCT06641089 | Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response | PHASE3 | Recruiting | 600 |
| NCT06641076 | Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic ... | PHASE3 | Active Not Recruiting | 960 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.